Shinji Kato
Papers
1
Total Citations
4
H-Index
1
About
Shinji Kato is a clinical researcher whose work centers on the chemopreventive and therapeutic potential of natural compounds in oncology, with a particular focus on prostate cancer. His most cited study, "Preliminary Evidence on Safety and Clinical Efficacy of Luteolin for Patients With Prostate Cancer Under Active Surveillance" (2025, 4 citations), provides early but promising evidence that luteolin—a flavonoid—may offer a safe, non-toxic intervention for men on active surveillance, addressing the critical unmet need for effective treatments that delay or prevent disease progression. This work builds on his prior foundational research demonstrating luteolin’s chemopreventive and chemotherapeutic properties in prostate cancer models. Kato’s contributions are notable for bridging preclinical findings to early-phase clinical investigation, offering a potential dietary-based strategy to manage prostate cancer recurrence after androgen deprivation therapy. Though his citation count is modest, his research is positioned at the forefront of integrating nutraceuticals into standard oncology care, with implications for reducing treatment burden and improving quality of life for patients.
Research Focus
Key Achievements
Top Papers
- 1